[Eye. Photo Credit to Pixibay]

In 2026, researchers analyzing FDA drug safety reports found a potential link between Wegovy use and a rare eye condition called ischemic optic neuropathy.

Wegovy is a prescription weight-loss medication containing semaglutide, primarily used to treat obesity and reduce health risks linked to excess weight.

The drug functions by mimicking a hormone called GLP-1, which helps regulate appetite, slows digestion, and makes patients feel full for longer.

Since its approval, Wegovy has gained immense popularity worldwide, with millions of prescriptions issued annually and demand becoming so high that supply shortages have occasionally occurred.

Its widespread use has revolutionized obesity treatment, but growing concerns about rare side effects have also attracted increasing scientific attention.

One particularly alarming concern surrounding Wegovy involves a rare but potentially serious eye condition called ischemic optic neuropathy (ION), sometimes referred to as an “eye stroke.”

This condition occurs when blood flow to the optic nerve — the structure responsible for transmitting visual information from the eye to the brain — is suddenly diminished or blocked.

As a result, patients may experience painless but sudden vision loss in one or both eyes, blurred sight, blind spots, or reduced color perception.

In severe cases, the damage may become permanent because optic nerve tissue cannot easily regenerate.

Although rare, the condition can dramatically affect a person’s quality of life because eyesight plays a central role in mobility, communication, education, and work.

To investigate whether Wegovy may contribute to this condition, researchers led by ophthalmology specialists, including Moiz Lakhani and Edward Margolin, analyzed reports submitted to the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) between 2017 and 2024.

Their research, published in the British Journal of Ophthalmology in March 2026, examined more than 30 million FDA adverse-event reports, including 31,774 cases involving semaglutide drugs such as Wegovy, Ozempic, and Rybelsus.

Rather than conducting laboratory experiments, the researchers used  pharmacovigilance, which studies real-world medication side effects by identifying patterns in large health databases.

The findings suggested a possible correlation between Wegovy and eye stroke.

Although Ozempic showed a greater number of total eye-stroke reports, researchers found that Wegovy demonstrated the strongest proportional safety signal for ischemic optic neuropathy.

Statistical analysis indicated that Wegovy users had an approximately 4.7 times higher reported risk of ION than Ozempic users, with men appearing more vulnerable than women.

While researchers suggested that Wegovy’s higher semaglutide dosage may play a role, they emphasized that the study showed an association rather than proof of direct causation.

Because FDA reports rely on voluntary submissions and do not account for every medical factor, scientists caution that further clinical studies are needed before definite conclusions can be reached.

If vision loss occurs, the effects on daily life can be substantial.

Individuals may find it challenging to perform everyday activities independently.

Sudden changes in eyesight can also lead to emotional distress, anxiety, and reduced self-esteem, particularly if vision impairment becomes permanent. 

Consequently, doctors advise Wegovy users to seek urgent medical attention if they notice sudden blurring or loss of vision.